[go: up one dir, main page]

MX2008013057A - Proteinas de enlace que comprenden regiones bisagra y regiones fc de inmunoglobulina que tienen funciones efectoras fc alteradas. - Google Patents

Proteinas de enlace que comprenden regiones bisagra y regiones fc de inmunoglobulina que tienen funciones efectoras fc alteradas.

Info

Publication number
MX2008013057A
MX2008013057A MX2008013057A MX2008013057A MX2008013057A MX 2008013057 A MX2008013057 A MX 2008013057A MX 2008013057 A MX2008013057 A MX 2008013057A MX 2008013057 A MX2008013057 A MX 2008013057A MX 2008013057 A MX2008013057 A MX 2008013057A
Authority
MX
Mexico
Prior art keywords
binding
binding proteins
hinge
domain
altered
Prior art date
Application number
MX2008013057A
Other languages
English (en)
Inventor
Baum Peter Robert
Erik Stephen Espling
Tan Phillip
Thompson Peter Armstrong
Original Assignee
Trubion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trubion Pharmaceuticals Inc filed Critical Trubion Pharmaceuticals Inc
Publication of MX2008013057A publication Critical patent/MX2008013057A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proveen proteínas de enlace que comprenden una o más de bisagra de inmunoglobulina de región Fc, y/o dominio CR3 y/o CR2 en donde una o más bisagras y/o región constante CH2 y/o dominio CH3 se modifica para alterar la afinidad de enlace de las proteínas de enlace y/o especificidad para un receptor cognado (e.g. un receptor Fc) y/o para proveer una o más especificidades de enlace nuevas a la bisagra y/o región constante que la inmunoglobulina sin modificar correspondiente no posee (e.g. afinidad para distintas clases de receptor cognado distinta de la clase de receptor cognado a la cual se enlaza específicamente la proteína de enlace sin modificar). Las proteínas de enlace de conformidad con la presente invención incluyen, por ejemplo, anticuerpos modificados, fragmentos de anticuerpos, proteínas de enlace recombinantes y proteínas de fusión dominio de enlace- inmunoglobulina molecularmente modificadas, incluyendo pequeños productos inmunofarmacéuticos modulares.
MX2008013057A 2006-04-14 2007-04-13 Proteinas de enlace que comprenden regiones bisagra y regiones fc de inmunoglobulina que tienen funciones efectoras fc alteradas. MX2008013057A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74489906P 2006-04-14 2006-04-14
PCT/US2007/066634 WO2007121354A2 (en) 2006-04-14 2007-04-13 Binding proteins comprising immunoglobulin hinge and fc regions having altered fc effector functions

Publications (1)

Publication Number Publication Date
MX2008013057A true MX2008013057A (es) 2009-04-07

Family

ID=38610404

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008013057A MX2008013057A (es) 2006-04-14 2007-04-13 Proteinas de enlace que comprenden regiones bisagra y regiones fc de inmunoglobulina que tienen funciones efectoras fc alteradas.

Country Status (9)

Country Link
US (1) US20080227958A1 (es)
EP (1) EP2007808A4 (es)
JP (1) JP2009538273A (es)
CN (1) CN101466733A (es)
AU (1) AU2007238034A1 (es)
BR (1) BRPI0710011A2 (es)
CA (1) CA2648849A1 (es)
MX (1) MX2008013057A (es)
WO (1) WO2007121354A2 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1772465T3 (da) 2005-01-05 2009-05-25 F Star Biotech Forsch & Entw Syntetiske immunoglobulindomæner med modificerede bindingsegenskaber i områder af molekylet, der ikke er komplementaritetsbestemmende regioner
AU2006326937B2 (en) * 2005-12-20 2012-01-19 Cephalon Australia Pty Ltd Anti-inflammatory dAb
BRPI0707425A2 (pt) 2006-02-01 2011-05-03 Arana Therapeutics Ltd construção de anticorpo de domìnio, molécula isolada de ácido nucleico, composição farmacêutica, e, métodos para detectar tnf-alfa humano em uma amostra, e para tratar um distúrbio
AT503889B1 (de) * 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
US7846434B2 (en) * 2006-10-24 2010-12-07 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
WO2009000006A1 (en) 2007-06-26 2008-12-31 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Display of binding agents
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
DK2496691T3 (en) 2009-11-02 2017-06-06 Univ Washington THERAPEUTIC NUCLEASE COMPOSITIONS AND PROCEDURES
EP2704737B1 (en) 2011-04-29 2018-01-10 University of Washington Therapeutic nuclease compositions and methods
CA2837546A1 (en) 2011-06-02 2012-12-06 Tufts University Dsrna/dna hybrid genome replication intermediate of metakaryotic stem cells
FR2980271B1 (fr) * 2011-09-16 2013-10-11 Cisbio Bioassays Procede de determination de la glycosylation d'un anticorps
SI2804878T1 (sl) 2012-01-20 2018-12-31 Genzyme Corporation Protitelesa proti-CXCR3
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
WO2013156054A1 (en) * 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
WO2013187495A1 (ja) * 2012-06-14 2013-12-19 中外製薬株式会社 改変されたFc領域を含む抗原結合分子
ES2876009T3 (es) 2012-12-27 2021-11-11 Chugai Pharmaceutical Co Ltd Polipéptido heterodimerizado
US9963513B2 (en) 2013-02-05 2018-05-08 Engmab Sàrl Method for the selection of antibodies against BCMA
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
WO2014159961A1 (en) 2013-03-14 2014-10-02 Beth Israel Deaconess Medical Center, Inc. Measurement of fgf21 as a biomarker of fructose metabolism and metabolic disease
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
US9822419B2 (en) 2013-05-20 2017-11-21 Bioventures, Llc GEP5 model for multiple myeloma
DK3063275T3 (da) 2013-10-31 2019-11-25 Resolve Therapeutics Llc Terapeutiske nuklease-albumin-fusioner og fremgangsmåder
CN113278076A (zh) 2013-11-11 2021-08-20 中外制药株式会社 含有改变了抗体可变区的抗原结合分子
CA2947605A1 (en) 2014-05-13 2015-11-19 Bioatla, Llc Conditionally active biological proteins
WO2016055592A1 (en) 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1
CA2966988A1 (en) * 2014-11-06 2016-05-12 Children's Research Institute, Children's National Medical Center Immunotherapeutics for cancer and autoimmune diseases
TWI740809B (zh) 2014-11-11 2021-10-01 日商中外製藥股份有限公司 包含經改變之抗體可變區之抗原結合分子的資料庫
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
TWI709571B (zh) * 2015-03-26 2020-11-11 日商Ｊｓｒ股份有限公司 免疫球蛋白結合蛋白質及使用此之親和性載體
SG10202007177XA (en) 2015-08-03 2020-09-29 Engmab Sarl Monoclonal antibodies against bcma
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
MA44483A (fr) 2016-03-24 2019-01-30 Millennium Pharm Inc Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
CN119120423A (zh) 2016-07-01 2024-12-13 分解治疗有限责任公司 优化的二核酸酶融合体和方法
WO2018014067A1 (en) 2016-07-19 2018-01-25 Teva Pharmaceuticals Australia Pty Ltd Anti-cd47 combination therapy
KR102687833B1 (ko) 2016-11-02 2024-07-24 브리스톨-마이어스 스큅 컴퍼니 다발성 골수종 치료를 위한 bcma 및 cd3에 대응하는 이중 특이적 항체 및 면역학적 약물의 복합용도
JP6550413B2 (ja) * 2017-02-24 2019-07-24 アール−ファーム・インターナショナル・リミテッド・ライアビリティ・カンパニーＲ−Ｐｈａｒｍ Ｉｎｔｅｒｎａｔｉｏｎａｌ， Ｌｌｃ オステオプロテゲリン由来の組成物およびその使用
EP3589320A4 (en) 2017-02-28 2020-12-23 Seagen Inc. ANTIBODIES UNDERGOING CYSTEINE MUTATION FOR CONJUGATION
BR112020003670A2 (pt) 2017-08-22 2020-09-01 Sanabio, Llc receptores de interferon solúveis e usos dos mesmos
TW201938194A (zh) 2017-12-05 2019-10-01 日商中外製藥股份有限公司 包含結合cd3及cd137的改變的抗體可變區之抗原結合分子
GB201804243D0 (en) * 2018-03-16 2018-05-02 Liverpool School Tropical Medicine Hinge sequences
EP3781130A4 (en) 2018-04-11 2022-01-26 Precision Molecular Inc. COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
WO2020007368A1 (zh) * 2018-07-06 2020-01-09 北京天成新脉生物技术有限公司 低adcc/cdc功能性单抗及其制备方法与应用
US12016885B2 (en) 2018-11-06 2024-06-25 Alsatech, Inc. Method of solubilizing TDP-43 protein aggregates in amyotrophic lateral sclerosis using a microvascular endothelial cell expressing an anti-TDP-43 Fab
CN111909268B (zh) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
CN112210005B (zh) * 2019-07-11 2024-03-26 京天成生物技术(北京)有限公司 低免疫原性低adcc/cdc功能的抗c5人源化单抗及其应用
CA3147883C (en) 2019-07-18 2024-01-02 Hanmi Pharm. Co., Ltd. Novel method for preparing long-acting drug conjugate through preparation of intermediate
AR121695A1 (es) 2020-03-31 2022-06-29 Chugai Pharmaceutical Co Ltd Moléculas de unión al antígeno multiespecíficas dirigidas a dll3 y sus usos

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888773A (en) * 1994-08-17 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Method of producing single-chain Fv molecules
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
AU2004204494B2 (en) * 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same

Also Published As

Publication number Publication date
CA2648849A1 (en) 2007-10-25
AU2007238034A1 (en) 2007-10-25
WO2007121354A3 (en) 2008-12-11
BRPI0710011A2 (pt) 2011-08-02
JP2009538273A (ja) 2009-11-05
EP2007808A2 (en) 2008-12-31
CN101466733A (zh) 2009-06-24
WO2007121354A2 (en) 2007-10-25
US20080227958A1 (en) 2008-09-18
EP2007808A4 (en) 2010-07-21

Similar Documents

Publication Publication Date Title
MX2008013057A (es) Proteinas de enlace que comprenden regiones bisagra y regiones fc de inmunoglobulina que tienen funciones efectoras fc alteradas.
WO2021041715A3 (en) Compositions including igg fc mutations and uses thereof
MX2009012319A (es) Polipeptidos que se unen a receptores fc con funciones efectoras modificadas.
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
NZ596865A (en) Single-chain multivalent binding proteins with effector function
MX2024004322A (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
UA86605C2 (ru) Антитело, которое содержит вариант исходного человеческого fс-участка
NZ585622A (en) Hepatitis c virus antibodies
EP1392359A4 (en) SPECIFIC TIE PROTEINS AND ITS USE
EP2684889A3 (en) Multivariable antigens complexed with targeting humanized monoclonal antibody
CR11030A (es) Proteinas de union, incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpos, que se unen especificamente a cd154 y sus usos
NZ587198A (en) Monoclonal antibodies against the rgm a protein and uses thereof
IN2015DN01361A (es)
WO2007106707A8 (en) Identification and engineering of antibodies with variant heavy chains and methods of using same
SE0401601D0 (sv) Protofibril specific antibodies and uses thereof
DK1562972T3 (da) Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
CY1108545T1 (el) Πρωτεϊνες υπομοναδας υποδοχεα κυτοκινης θηλαστικου, σχετικα αντιδραστηρια και μεθοδοι
MY155144A (en) NEW ANTIBODIES SPECIFIC OF THE ß-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC AGENTS OR DRUGS
EA200600905A1 (ru) АНТИГЕНСВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
EP3300739A3 (en) Antibodies and related molecules that bind to 161p2f10b proteins
WO2007067596A3 (en) Methods and compositions for needleless delivery of antibodies
WO2008098917A3 (en) Novel antibodies against igf-ir
EA200870208A1 (ru) Конструкт однодоменного антитела
WO2003078468A3 (de) Verwendung einer an cd28 bindenden wirksubstanz zur herstellung einer pharmazeutischen zusammensetzung
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения

Legal Events

Date Code Title Description
FA Abandonment or withdrawal